Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38501 SCHOLAR ROCK HOLDING CORPORATION (Exact name of Registrant as specified in its charter) Delaware 82-3750435 ...

Deep Insights Advancing Impactful Medicines 41st Annual J.P. Morgan Healthcare Conference | January 2023 ...

Deep Insights Advancing Impactful Medicines August 2022 ScholarRock Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for apitegromab, SRK-181, and other product candidates and indication se ...

Deep Insights Advancing Impactful Medicines August 2022 ScholarRock Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for apitegromab, SRK-181, and other product candidates and indication se ...

Deep Insights Advancing Impactful Medicines 40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 ScholarRock. | --- ...

Deep Insights, Impactful Medicines August 2021 ScholarRock. Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for its product candidates, its disease indication selection and timing for such ...

Apitegromab Positioned to be the Potential Next Transformative Therapy for Patients Suffering with SMA KOL Event and Panel Discussion June 15, 2021 & ScholarRock. Disclaimers Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. ("Scholar Rock"), including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results fr ...

Deep Insights, Impactful Medicines September 2020 ScholarRock. Disclaimers Various statements in this presentation concerning Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability o ...

Deep Insights, Impactful Medicines August 2020 ScholarRock. Disclaimers Various statements in this presentation concerning Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability of S ...

Scholar Rock Holding Corp. (NASDAQ:SRRK) Q2 2020 Results Conference Call August 7, 2020 8:00 AM ET Company Participants Catherine Hu - Vice President, Investor Relations and Corporate Communications Tony Kingsley - President & CEO Yung Chyung - Chief Medical Officer Ted Myles - CFO and Head of Business Operations Conference Call Participants Michael Yee - Jefferies Madhu Kumar - Baird David Nierengarten - Wedbush Securities Marc Frahm - Cowen and Company Operator Ladies and gentlemen, thank you for standing ...